Rethinking heart failure clinical trials: the heart failure collaboratory
Frontiers in Cardiovascular Medicine · 24.01.2024 · 11
DOI: 10.3389/fcvm.2024.1350569 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 24.01.2024. Verfasst von Mutaz Alkalbani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Inova Schar Heart and Vascular, Falls Church, VA, United States. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The Heart Failure Collaboratory (HFC) is a consortium of stakeholders in the heart failure (HF) community that aims to improve the infrastructure of clinical research to promote development of novel therapies for patients. Since its launch in 2018, HFC has implemented several solutions to tackle obstacles in HF clinical research including training programs to increase the number of clinicians skilled in conducting clinical trials, novel study designs, and advocacy for a diverse and inclusive HF research ecosystem. We highlight some of the HFC successes since its establishment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Inova Schar Heart and Vascular, Falls Church, VA, United States.
Zitieren
APA
Alkalbani, M., & Psotka, M. A. (2024). Rethinking heart failure clinical trials: the heart failure collaboratory. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1350569
Vancouver
Alkalbani M, Psotka MA. Rethinking heart failure clinical trials: the heart failure collaboratory. Frontiers in Cardiovascular Medicine. 2024;11. doi:10.3389/fcvm.2024.1350569
BibTeX
@article{Alkalbani2024,
author = {Alkalbani, Mutaz and Psotka, Mitchell A},
title = {Rethinking heart failure clinical trials: the heart failure collaboratory},
journal = {Frontiers in Cardiovascular Medicine},
year = {2024},
volume = {11},
doi = {10.3389/fcvm.2024.1350569}
}
EUVIMED